Results from a recent survey have prompted questions about the influence of GLP-1s on the obesity rate of U.S. adults.
A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...
Two new studies identified additional benefits of medications like semaglutide—the active ingredient in Novo Nordisk's ...
Reports of pulmonary aspiration and difficulties in diagnosing gastrointestinal complications in the perioperative period have highlighted the need for clear clinical guidance to manage these patients ...
Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...
The holidays are a time known for feasting on delicious food, but that might not be possible for people taking weight-loss drugs.
As drugs like Ozempic and Wegovy keep flying off the shelves, more and more people are taking the drug into their own hands ...
The use of GLP-1s is linked to improved inflammatory bowel disease outcomes in patients with concomitant inflammatory bowel ...
A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.